JP2025515191A5 - - Google Patents
Info
- Publication number
- JP2025515191A5 JP2025515191A5 JP2024565319A JP2024565319A JP2025515191A5 JP 2025515191 A5 JP2025515191 A5 JP 2025515191A5 JP 2024565319 A JP2024565319 A JP 2024565319A JP 2024565319 A JP2024565319 A JP 2024565319A JP 2025515191 A5 JP2025515191 A5 JP 2025515191A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- syndrome
- fusion protein
- autoimmune
- protein according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB202206673 | 2022-05-06 | ||
| GB2206673.2 | 2022-05-06 | ||
| PCT/IB2023/054722 WO2023214388A1 (en) | 2022-05-06 | 2023-05-05 | Novel cd200 fusion proteins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025515191A JP2025515191A (ja) | 2025-05-13 |
| JP2025515191A5 true JP2025515191A5 (enExample) | 2026-05-14 |
Family
ID=86609511
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024565319A Pending JP2025515191A (ja) | 2022-05-06 | 2023-05-05 | 新規ｃｄ２００融合タンパク質 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20260116946A1 (enExample) |
| EP (1) | EP4519298A1 (enExample) |
| JP (1) | JP2025515191A (enExample) |
| KR (1) | KR20250025619A (enExample) |
| CN (1) | CN119522234A (enExample) |
| AU (1) | AU2023265174A1 (enExample) |
| CA (1) | CA3251039A1 (enExample) |
| IL (1) | IL316697A (enExample) |
| MX (1) | MX2024013669A (enExample) |
| WO (1) | WO2023214388A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2626300A (en) * | 2022-12-08 | 2024-07-24 | Ducentis Biotherapeutics Ltd | Mutated CD200 proteins and methods of use therof |
| WO2025106841A1 (en) * | 2023-11-15 | 2025-05-22 | The University Of Chicago | Methods and compositions for inducing antigen specific tolerance |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0606217B2 (en) | 1991-06-27 | 2008-12-03 | Bristol-Myers Squibb Company | Ctl4a receptor, fusion proteins containing it and uses thereof |
| US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
| JP2002541210A (ja) | 1999-04-13 | 2002-12-03 | シェーリング コーポレイション | 哺乳動物ｏｘ２タンパク質および関連試薬の新規な使用 |
| US8367805B2 (en) * | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| EP2121015A4 (en) | 2007-01-11 | 2010-03-24 | Boehringer Ingelheim Int | CD200 AND RECEPTOR THEREFOR, CD200R AND BONE MASS MODULATION BY ESTEOKLASTENDIFFERENZIERUNG |
| GB201608197D0 (en) * | 2016-05-10 | 2016-06-22 | Ducentis Biotherapeutics Ltd | Novel proteins |
-
2023
- 2023-05-05 AU AU2023265174A patent/AU2023265174A1/en active Pending
- 2023-05-05 CN CN202380044583.5A patent/CN119522234A/zh active Pending
- 2023-05-05 IL IL316697A patent/IL316697A/en unknown
- 2023-05-05 US US18/863,179 patent/US20260116946A1/en active Pending
- 2023-05-05 EP EP23727672.0A patent/EP4519298A1/en active Pending
- 2023-05-05 CA CA3251039A patent/CA3251039A1/en active Pending
- 2023-05-05 WO PCT/IB2023/054722 patent/WO2023214388A1/en not_active Ceased
- 2023-05-05 KR KR1020247040650A patent/KR20250025619A/ko active Pending
- 2023-05-05 JP JP2024565319A patent/JP2025515191A/ja active Pending
-
2024
- 2024-11-05 MX MX2024013669A patent/MX2024013669A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI291468B (en) | Crystal of etanercept and its preparing method and use | |
| US11203628B2 (en) | CD200 mutants and its uses | |
| JP2015526064A5 (enExample) | ||
| JP2020528894A5 (enExample) | ||
| EP3464347B1 (en) | Cysteine-optimized stradomers | |
| JP2024542096A5 (enExample) | ||
| US20260116946A1 (en) | Novel cd200 fusion proteins | |
| US20250026805A1 (en) | Novel proteins | |
| JP2025516364A5 (enExample) | ||
| WO2025087363A1 (zh) | 用TACI-Fc融合蛋白治疗自身免疫性脑炎的方法 | |
| AU2023391468A1 (en) | Taci-fc fusion proteins for multifunctional inhibition of baff, april, and neonatal fc receptor | |
| JP2024546654A5 (enExample) | ||
| NZ747665B2 (en) | Cd200 mutant and its uses | |
| JP2022513490A5 (enExample) | ||
| RU2023135361A (ru) | Белки, которые связываются с cd80 и/или cd86 и ox40l | |
| JP2025516364A (ja) | 新規ｃｄ２００融合タンパク質 | |
| CN121152636A (zh) | 用TACI-Fc融合蛋白治疗ANCA相关性血管炎的方法 | |
| JP2024524880A5 (enExample) | ||
| KR20260007620A (ko) | Cd200 융합 단백질 | |
| BR122025011067A2 (pt) | Composição que compreende um anticorpo anti-il-5 e composição farmacêutica que compreende a dita composição | |
| BR122025011033A2 (pt) | Composição que compreende um anticorpo anti-il-5, uso terapêutico da mesma, bem como composição farmacêutica que compreende a dita composição |